20 results about "Contragestazol" patented technology

This invention provides the application of CTH inhibitors and / or xCT inhibitors in the preparation of drugs for inhibiting mammalian embryo implantation, relating to the field of pharmaceutical technology. This invention verifies the efficacy of cystathionine-γ-lyase (CTH) inhibitors and / or solute carrier family 7 member 11 (xCT) inhibitors in inhibiting mammalian embryo implantation. The results show that xCT inhibitors and / or CTH inhibitors can significantly inhibit the proliferation of luteinized granulosa cells and progesterone secretion in mouse models. Furthermore, in vivo injection of xCT inhibitors and / or CTH inhibitors into mouse models not only significantly inhibits ovulation and the maturation rate of released oocytes, but also significantly reduces the formation of functional corpus luteum and embryo implantation. Therefore, this application provides new ideas and methods for the development of contraceptive drugs.

The application relates to the technical field of animal models, in particular to a modeling method and an evaluation method of an animal menstrual dysmenorrhea model and application, wherein the animal with removed ovaries is injected with estrogen, progesterone and oxytocin, the pharmacological injection of progesterone can reduce the harm and mortality rate of the animal caused by the implantation and removal of a progesterone release body in the prior art, the surgical stress of the animal is reduced, the injection time of the progesterone in the application is 7-9 days, and the animal menstrual dysmenorrhea model is obtained after the progesterone is withdrawn for 16 hours; after evaluation by the evaluation method, compared with the non-menstrual process of the dysmenorrhea model in the prior art, the animal menstrual dysmenorrhea model can better simulate the pathophysiological process of human dysmenorrhea, promote the development of clinical treatment, and effectively help patients to relieve pain.

The present invention relates to a method for detecting steroid hormones in serum, comprising the following steps: (1) adding 0.1 to 20 mg of a magnetic solid phase extractant to each milliliter of a sample to be tested, mixing, magnetically separating, and removing liquid; adding a washing solution, mixing, magnetically separating, and removing liquid; adding an eluent for elution, mixing, magnetically separating, and collecting the eluent to obtain a test solution; (2) detecting the hormone content in the test solution by liquid chromatography and tandem mass spectrometry; wherein the hormone is selected from any one of testosterone, androstenedione, dihydrotestosterone, dehydroepiandrosterone sulfate, and 17α-hydroxyprogesterone or a combination thereof; the magnetic solid phase extractant comprises a magnetic core ferrosoferric oxide, a middle layer structure silica wrapping the magnetic core, and an outer layer mesoporous structure, wherein the outer layer mesoporous structure is selected from any one of polystyrene and polystyrene divinylbenzene or a combination thereof. The present invention has the characteristics of good stability, high accuracy and sensitivity, strong specificity, high recovery rate, simple and controllable operation, fast analysis speed, etc., and can be used for simultaneous quantitative detection of multiple hormones in clinical practice.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

A method for co-administrating hydroxyprogesterone caproate, tyrosine kinase inhibitor, and / or anti-PD-I / PD-LI an-1 tibodies for tumor treatment. The present application also provides a corresponding pharmaceutical use and a pharmaceutical product. Co-administration with hydroxyprogesterone caproate can further improve the therapeutie effect of lenvatinib and anti-PD-I / PD-L1 antibodies against tumors.

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.

Embodiments of the invention comprise a test strip configured to detect one or more metabolites of progesterone in urine, and optionally further detect one or more additional metabolites or hormones in urine within the same test strip. Embodiments of the invention are methods of utilizing such a test strip in association with avoidance of pregnancy, detection of menopause, and in association with fertility planning purposes. Embodiments of the invention are associated with the incorporation of a test strip within a testing kit, optionally further comprising a digital reader.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg / kg to 18 mg / kg, preferably 8 to 12 mg / kg, more preferably 8 to 10 mg / kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

Provided in the present invention is a pharmaceutical composition comprising hydroxyprogesterone caproate and an additional therapeutic agent for treating tumors, wherein the additional therapeutic agent is preferably a monoclonal antibody against PD-1 or PD-L1. Further provided in the present invention are a method for increasing the number of tumor infiltrating lymphocytes (TIL) as required and a method for treating cancers in a subject in need thereof, which comprises providing the hydroxyprogesterone caproate to the subject.

Compositions and methods for the delivery of progestin hormones that have binding affinity to the Sex Hormone Binding Globulin (SHBG) are disclosed. The compositions combine such progestins with non-progestin SHBG ligands to displace at least part of the progestin from SHBG in the blood plasma, thereby increasing its bioavailability. Also disclosed are methods to modulate progestin and estrogen levels in the blood through the use of SHBG binding and displacement, to optimize the effectiveness of formulations for contraception and minimize the side effects and adverse events.

Described are combined oral contraceptive compositions with reduced cardiovascular effects and methods using them. In some embodiments, the methods relate to contraceptive methods or methods for treating dysmenorrhea with reduced cardiovascular effects, such as reduced venous thromboembolism (VTE) risk. The methods comprise administering to a female subject an effective amount of an estetrol component and a progestogenic component. The methods enjoy a favourable profile for thromboembolism compared to currently available methods which employs contraceptives from the so-called second, third or fourth generation.

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.

The invention relates to the technical field of contraceptives, and discloses a levonorgestrel long-acting slow-release implant and a preparation method thereof, the levonorgestrel long-acting slow-release implant comprises the following components by mass: 10-20 parts of a levonorgestrel bulk drug, 25-35 parts of PCL, 40-50 parts of PLGA, 3-8 parts of a solid dispersant, and 3-8 parts of an injection solvent. According to the invention, a composite structure of a levonorgestrel microcrystalline core with a particle size of 5-20 [mu] m and a PLGA-PCL gradient degradation coating is adopted, and an injection solvent is mixed to form a minimally invasive injection suspension; the preparation method comprises the following steps: preparing microcrystals through anti-solvent precipitation, preparing a gradient coating through fluidized bed coating, and mixing to prepare a suspension, thereby obtaining the levonorgestrel long-acting slow-release implant. After being subjected to hypodermic injection through a 27G narrow needle, the nanomaterial is self-assembled into a 3mm columnar solid, can be completely degraded into CO2 and H2O, and has long-term effectiveness, minimally invasive property, degradability and drug release stability.

The invention relates to the technical field of animal models, in particular to a modeling method of an animal menstrual dysmenorrhea model, an evaluation method and application of the animal menstrual dysmenorrhea model. The animal menstrual dysmenorrhea model is characterized in that the animal menstrual dysmenorrhea model is obtained after the progesterone releaser is implanted and taken out, the injury to the animal caused by implantation and taking out of the progesterone releaser in the prior art can be relieved through pharmacologic injection of the progesterone, the death rate is reduced, the operation pressure of the animal is relieved, the injection administration time of the progesterone is 7-9 days, and the animal menstrual dysmenorrhea model is obtained after the progesterone is withdrawn for 16 hours; after evaluation by the evaluation method, compared with a dysmenorrhea-like model without a menstrual sample process in the prior art, the animal menstrual sample dysmenorrhea model disclosed by the invention can better simulate the pathophysiological process of human dysmenorrhea, promote the development of clinical treatment and practically help a patient to relieve pain.

The invention discloses a method for measuring the content of progesterone and testosterone in animal waste. The method comprises the following steps: extracting fresh animal excrement by adopting an ethyl acetate-methyl tert-butyl ether solution, carrying out liquid nitrogen blowing and drying on the extracted animal excrement, adding methanol for dissolving, adding water, and uniformly mixing, so as to obtain a sample extracting solution; carrying out enrichment purification treatment on the sample extracting solution by adopting a combined column strategy of a C18 SPE column and an amino SPE column to obtain a solution to be detected; and detecting the contents of the testosterone and the progesterone in the liquid to be detected by adopting an LC-MS method to obtain the contents of the progesterone and the testosterone in the animal waste. According to the method disclosed by the invention, the solid-phase extraction columns are combined for use, so that effective enrichment and purification of testosterone and progesterone in the excrement sample can be realized, interference matrixes in the excrement sample are efficiently removed, the requirements of an LC-MS method on accurate detection of testosterone and progesterone are met, the result is accurate and reliable, and the method is suitable for large-scale popularization and application. The method has very important practical significance for mastering the reproductive cycle of animals, preventing and treating diseases or managing breeding.

A drug delivery device for treating one or more symptoms of menopausal in a subject comprising intravaginal insertion of an implantable drug delivery device into the subject wherein the implantable drug delivery device comprises an estrogen and a progesterone, and further wherein the implantable drug delivery device provides a baseline adjusted homeostatic plasma estrogen concentration of from about 15 pg / mL to about 50 pg / mL in the subject.

The invention discloses a system for promoting in-vitro differentiation of chicken oogonial stem cells and forming blastocysts, and belongs to the technical field of stem cell differentiation culture. According to the invention, retinoic acid (RA) and vitamin C (VC) are added on the basis of an oogonial stem cell culture medium to induce cells to start meiosis, and then follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), glial cell-derived neurotrophic factor (GDNF), progesterone (P4) and rosiglitazone are further added on the basis of the culture medium containing RA and VC to promote the recovery of meiosis, so that the effect of promoting meiosis is achieved. A complete system that the chicken oogonial stem cells are differentiated in vitro and form blastocysts is creatively established by inducing formation of secondary oocytes, direct evidence is provided for in-vitro reconstruction of poultry ovum generation, and a technical basis and application prospects are provided for preservation of female germ cells and large-scale production of the chicken oocytes.

The present disclosure describes a method of quantifying analyte levels using gold nanoparticles. The present disclosure also describes a device to quantify analyte levels using gold nanoparticles and image processing of pixels isolated from a single vector. The methods, devices, and systems of the disclosure can be used to quantify analytes such as luteinizing hormone, progesterone, estradiol, or testosterone.

Device (2) and method for determining a value quantifying a risk of relapse of breast cancer for a patient A device for determining a value quantifying a risk of relapse of breast cancer for a patient comprises a data storage (114) adapted to store patient data associating, for each given patient at a least one whole histological slide image and patient clinical data comprising at least a tumor size, a number of positive lymph nodes, a tumor grade, and progesterone receptor (PR) positivity value, a feature extractor (1210, 1220) arranged to receive a whole histological slide image and associated patient clinical data, to derive tumor architecture features comprising a tumor area, an invasive tumor nest density, a tumor density at the invasive front, and an in situ tumor nest density, tumor microenvironment features comprising a border composition of in situ tumor, a variance of healthy gland size, an inflammatory stroma area, and an average nuclei size of stromal cells, and mitosis features comprising a mitotic hotspot count and a mitotic density, and to return a patient feature vector comprising said tumor architecture features, said tumor microenvironment features, said mitosis features, and features derived from said associated patient clinical data, a risk classifier (1230) using a machine learning module which is arranged to receive a patient feature vector as an input and to return a value quantifying a risk of relapse of breast cancer for a patient, said machine learning module having been trained with a dataset of labelled patient feature vectors and being arranged to return a risk value. This device is arranged to receive a set of patient data of a given patient, to provide at least some of said given patient's whole histological slide image and said given patient's clinical data as inputs to the feature extractor, to provide at least some of the resulting patient feature vectors to the risk classifier, and to return a value quantifying a risk of relapse of breast cancer for a patient for said given patient based on the outputs of the risk classifier.